Cell>Point submits IND for heart agent

Jun 22, 2010

Cell>Point of Centennial, CO, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for a radiopharmaceutical for imaging coronary artery disease.

The IND covers a phase Ib/II trial of the company's technetium-99m-labeled glucosamine (Tc-99m EC-G) diagnostic imaging agent. It is designed to evaluate patients with cardiovascular issues, such as reduced blood supply (ischemia), recent heart attacks, and questionable heart muscle cell viability.

The study will attempt to determine if Tc-99m EC-G can be used as an alternative to traditional myocardial perfusion imaging (MPI) agents, and be target-specific for the region of ischemia.

Preclinical studies have shown that the agent targets and concentrates in ischemic heart muscle tissue, according to Cell>Point.

Cell>Point names Rollo as president, September 13, 2006

Biotech firm Cell>Point sees promise for oncology SPECT, May 20, 2005

Philips adds molecular imaging partnership, September 29, 2003

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$